Caribou Biosciences
Caribou Biosciences is a genome-editing biopharmaceutical company associated with CRISPR-edited allogeneic cell therapies. On 6 October 2026, it announced a review of strategic alternatives and plans to discontinue further development of vispa-cel and CB-011, alongside workforce and cost reductions. The ranking records the 2026 assessment; the later strategic review and planned programme discontinuations are material context for that assessment.
- Highest 2026 tier: Tier III
- Cell & Gene Therapy Developers
- 1 ranking category
Overview
Caribou Biosciences is a genome-editing biopharmaceutical company associated with CRISPR-edited allogeneic cell therapies. On 6 October 2026, it announced a review of strategic alternatives and plans to discontinue further development of vispa-cel and CB-011, alongside workforce and cost reductions. The ranking records the 2026 assessment; the later strategic review and planned programme discontinuations are material context for that assessment.
Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. Caribou Biosciences contributes a credible combination of these characteristics.
Published assessment: Top 30 Cell & Gene Therapy Developers 2026 — Caribou Biosciences.
Firm facts
| Public identity | Caribou Biosciences |
| Legal incorporation | October 2011 (Delaware corporation) |
| Headquarters / principal executive offices | Berkeley, California, United States |
| Institution type | Genome-editing biopharmaceutical company |
| Primary focus | Cell & Gene Therapy Developers |
| Highest 2026 ranking tier | Tier III |
Contents
Activities in published assessments
Top 30 Cell & Gene Therapy Developers 2026 — Caribou Biosciences
Caribou Biosciences is a genome-editing biopharmaceutical company associated with CRISPR-edited allogeneic cell therapies. On 6 October 2026, it announced a review of strategic alternatives and plans to discontinue further development of vispa-cel and CB-011, alongside workforce and cost reductions. The ranking records the 2026 assessment; the later strategic review and planned programme discontinuations are material context for that assessment.
Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. Caribou Biosciences contributes a credible combination of these characteristics.
Principal activities
Caribou Biosciences is assessed using public institutional information and category-specific editorial research.
Core capability
Cell & Gene Therapy Developers
Client relevance
Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.
Execution and verification
Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.
Sector and mandate coverage
Primary category
Cell & Gene Therapy Developers
Institutional context
Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.
Market position
Caribou Biosciences is assessed using public institutional information and category-specific editorial research.
Caribou Biosciences is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier III.
Competitive context
The relevant peer set varies by category, geography, client segment and mandate. Caribou Biosciences should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.
Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.
Leadership and governance
Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.
Corporate and public information
The public-facing organization is identified here as Caribou Biosciences. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.
Corporate and disclosure information
| Organization | Caribou Biosciences |
| Verification note | Confirm legal entity, licenses, offices and engagement terms directly before appointment or use. |
Rankings and recognition
Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.
Related Economy analysis
Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:
- Healthcare Rankings and the New Economics of Expertise
- Healthcare Market Structure Is Opening a New Lane for Specialist Providers
- Healthcare Rankings and the New Geography of Distributed Care
Related institutions and subjects
Strategic review and operating transition
Caribou’s 6 October 2026 announcement disclosed a strategic review and planned discontinuation of vispa-cel and CB-011 development. Its Form 8-K dates board approval to 2 October and describes phased workforce departures expected mainly in the fourth quarter, with a smaller team supporting the review and wind-down. The filing also reports an ongoing long-term patient follow-up study. These disclosures describe a transition plan, rather than confirming a completed sale or dissolution.
The company’s investor FAQ identifies Berkeley, California as its headquarters location and distinguishes its 2011 foundation and incorporation from its July 2021 IPO.
Sources and data transparency
Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.
- Healthcare Ranking — Top 30 Cell & Gene Therapy Developers 2026 — 2026 inclusion and tier classification.
- The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
- The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
- The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.
Corrections and Updates
Factual corrections, updated institutional information, and supporting references may be submitted through The Economy Portal. All proposed changes are subject to editorial verification before publication.